Phase I trial of daily PI3Kα inhibitor BYL719 plus letrozole (L) or exemestane (E) for patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC). This is an ASCO Meeting ...
Celcuity's gedatolisib, a pan-PI3K/mTOR inhibitor for advanced breast cancer, shows strong early efficacy and is in pivotal Phase 3 trials, yet remains undervalued. The company has a healthy cash ...
Addressing Administrative and Regulatory Burden in Cancer Clinical Trials: Summary of a Stakeholder Survey and Workshop Hosted by the American Society of Clinical Oncology and the Association of ...
Celcuity's lead asset, Gedatolisib, is a dual PI3K/mTOR inhibitor targeting various cancers, currently in multiple Phase 3 trials. Gedatolisib shows promising efficacy and safety, especially in ...
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert ...
Kazia Therapeutics Ltd. raised AU$50 million (US$33.15 million) in a private placement of equity securities to advance lead candidate paxalisib, a brain-penetrant dual PI3K/mTOR inhibitor in clinical ...
This study is carried out by Prof. Qiang Liu (Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University). In this study, researchers found that the palbociclib-resistant breast cancer ...
As previously presented, gedatolisib + palbociclib + fulvestrant (“gedatolisib triplet”) and gedatolisib + fulvestrant (“gedatolisib doublet”) reduced the risk of disease progression or death versus ...
HOUSTON -- Two-thirds of patients with PI3K-mutant brain metastases responded to the maximum tolerated dose (MTD) of the small-molecule inhibitor paxalisib plus radiation therapy (RT), a small phase I ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results